Association between SLCO1B1 −521T>C and −388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis
Open Access
- 19 August 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in SpringerPlus
- Vol. 5 (1), 1-16
- https://doi.org/10.1186/s40064-016-2912-z
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Efficacy of Anti-Leishmania Therapy in Visceral Leishmaniasis among HIV Infected Patients: A Systematic Review with Indirect ComparisonPLoS Neglected Tropical Diseases, 2013
- The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced MyopathyCancer Cell, 2012
- Individualized Risk for Statin-Induced Myopathy: Current Knowledge, Emerging Challenges and Potential SolutionsPharmacogenomics, 2012
- Cerivastatin, genetic variants, and the risk of rhabdomyolysisPharmacogenetics and Genomics, 2011
- Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS StudyClinical Pharmacology & Therapeutics, 2010
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side EffectsJournal of the American College of Cardiology, 2009
- Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization StudiesAmerican Journal of Epidemiology, 2009
- Genetic determinants of statin intoleranceLipids in Health and Disease, 2007
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986